Advanced Viral Research Corp. Announces Completion of Accrual in First Part of Diabetes Study
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that it has completed enrollment of subjects in the first part of the Phase I study in Type 2 diabetic patients. In this study, 30 subjects with type 2 diabetes, being treated with sulfonylureas and/or metformin, were expected to be enrolled. The primary objective was to explore the effect of daily doses 4.0 ml of AVR118 given subcutaneously on blood glucose, as compared to subjects not receiving AVR118. All 30 subjects have been enrolled.
Earlier this year, the Company amended the protocol for this study to include an additional 12 subjects at a dose of 1.0 ml of AVR118 given subcutaneously daily for 15 days, followed by one week of dosing every other day. Accrual of the additional 12 patients is currently ongoing.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. |
